Epilepsy is one of the most common neurological disorders across all age groups. [1] While anti-seizure medication (ASM) is the first line treatment, only two thirds of patients achieve seizure freedom. [2] Although many new ASM have been developed over the past decades, the rate of patients with drug-resistant epilepsy (DRE) has not changed. [2] DRE can have adverse effects on cognition and neurodevelopment. [3,4] Patients with DRE have an increased risk of sudden unexpected death in epilepsy (SUDEP) and poorer health-related quality of life.
10
SEP
SEP
0